ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes

Annals of Surgical Oncology

Volumn 13, Issue 10, 2006, Pages 1296-1321

  Guillem, José G ^a   Wood, William C ^b   Moley, Jeffrey F ^c   Berchuck, Andrew ^d   Karlan, Beth Y ^e   Mutch, David G ^c   Gagel, Robert F ^f   Weitzel, Jeffrey ^g   Morrow, Monica ^h   Weber, Barbara L ⁱ   Giardiello, Francis ^j   Rodriguez Bigas, Miguel A ^f   Church, James ^k   Gruber, Stephen ^l   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

more..

Author keywords

Familial adenomatous polyposis; Hereditary cancer; HNPCC; Multiple endocrine neoplasia; Risk reducing surgery; Surgical prophylaxis

Indexed keywords

ADENOMATOUS POLYP; BREAST CANCER; CANCER RISK; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL SURGERY; CONFERENCE PAPER; CONSENSUS; DESMOID TUMOR; ENDOMETRIUM CANCER; FAMILIAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; ILEORECTAL ANASTOMOSIS; MEDICAL SOCIETY; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE RET; OVARY CANCER; PROCTOCOLECTOMY; PROPHYLAXIS; RISK REDUCTION; SALPINGOOOPHORECTOMY; SURGICAL APPROACH; SURGICAL TECHNIQUE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TOTAL COLON RESECTION; TREATMENT INDICATION;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEDICAL ONCOLOGY; MUTATION; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; RISK; RISK ASSESSMENT; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 33748936176     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9036-6     Document Type: Conference Paper

References (215)

1. Garber J, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 10:276-92.
2. Lynch HT, Krush AJ. Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 1971; 133:644-8.
3. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset breast cancer to chromosome 17q21. Science 1990; 250:1684-9.
4. Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338:82-3.
5. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science 1994; 266:66-71.
6. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-90.
7. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome?. Ann Intern Med 1969; 71:747-52.
8. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden's disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-7.
9. Nelen MR, van Staveren WC, Peeters EA, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997; 6:1383-7.
10. Swift M, Chase CL, Morrell D. Cancer predispositions of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 1990; 46:21-7.
11. Srivastava A, McKinnon W, Wood ME. Risk of breast and ovarian cancer in women with strong family histories. Oncology (Huntingt) 2001; 15:889-902.
12. Available at: http://www.myriadtests.com/provider/mutprev.htm. Accessed: November 14, 2003.
13. Available at: http://www.astor.som.jhmi.edu/brcapro/. Accessed: November 14, 2003.
14. Meiser B, Butow P, Barratt A, et al. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 1999; 75:122-9.
15. Klamer TW, Donegan WL, Max MH. Breast tumor incidence in rats after partial mammary resection. Arch Surg 1983; 118:933-5.
16. Wong JH, Jackson CF, Swanson JS, et al. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7,12-dimethylbenzanthracene-induced breast cancer. Surgery 1986; 99:67-71.
17. Nelson H, Miller SH, Buck D, et al. Effectiveness of prophylactic mastectomy in the prevention of breast tumor in C3H mice. Plast Reconstr Surg 1989; 83:662-9.
18. Baasch M, Nielsen SF, Engholm G, et al. Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 1996; 73:961-3.
19. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340:77-84.
20. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159-64.
21. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055-62.
22. Carlson GW, Bostwick J III, Styblo TM, et al. Skin-sparing mastectomy. Oncologic and reconstructive considerations. Ann Surg 1997; 225:570-5.
23. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609-15.
24. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2000; 18:100S-103S.
25. Narod SA, Brunet JS, Ghadirian P, et al. Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356:1876-81.
26. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619-26.
27. Brekelmans CT, Seynaeve C, Bartels CC, et al. Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19:924-30.
28. Kuhl CK, Schrading S, Leutner CC, et al. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: first mid-term results of a multimodality clinical screening trial (abstract 4). Proc Am Soc Clin Oncol 2003; 22:2.
29. Kriege M, Brekelmans CTM, Boetes C, et al. MRI screening for breast cancer in women with high familial and genetic risk: first results of the Dutch MRI screening study (MRISC) (abstract 5). Proc Am Soc Clin Oncol 2003; 22:2.
30. Guillem JG, Smith AJ, Puig-La Calle J, et al. Gastrointestinal polyposis syndromes. Curr Probl Surg 1999; 36:217-324.
31. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-32.
32. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348:791-9.
33. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003; 362:39-41.
34. Muller A, Fishel R. Mismatch repair and the hereditary nonpolyposis colorectal cancer syndrome (HNPCC). Cancer Invest 2002; 20:102-9.
35. Wheeler JM, Bodmer WF, Mortensen NJ. DNA mismatch repair genes and colorectal cancer. Gut 2000; 47:148-53.
36. Church J, Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003; 46:1001-12.
37. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020-7.
38. Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002; 45:127-34.
39. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:198-213.
40. Debinski HS, Love S, Spigelman AD, et al. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology 1996; 110:1028-30.
41. Guillem JG, Smith AJ, Calle JP, et al. Gastrointestinal polyposis syndromes. Curr Probl Surg 1999; 36:217-323.
42. Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg 2003; 238:221-8.
43. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222:120-7.
44. Vasen HF, van der Luijt RB, Slors JF, et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996; 348:433-5.
45. Bertario L, Russo A, Radice P, et al. Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. Hereditary Colorectal Tumors Registry. Ann Surg 2000; 231:538-43.
46. Church J, Burke C, McGannon E, et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003; 46:1175-81.
47. Church J, Burke C, McGannon E, et al. Predicting polyposis severity by proctoscopy: how reliable is it?. Dis Colon Rectum 2001; 44:1249-54.
48. Sarre RG, Jagelman DG, Beck GJ, et al. Colectomy with ileorectal anastomosis for familial adenomatous polyposis: the risk of rectal cancer. Surgery 1987; 101:20-6.
49. Bulow C, Vasen H, Jarvinen H, et al. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000; 119:1454-60.
50. Wu JS, Paul P, McGannon EA, et al. APC genotype, polyp number, and surgical options in familial adenomatous polyposis. Ann Surg 1998; 227:57-62.
51. van Duijvendijk P, Vasen HF, Bertario L, et al. Cumulative risk of developing polyps or malignancy at the ileal pouchanal anastomosis in patients with familial adenomatous polyposis. J Gastrointest Surg 1999; 3:325-30.
52. Remzi FH, Church JM, Bast J, et al. Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. Dis Colon Rectum 2001; 44:1590-6.
53. Fazio VW, Tjandra JJ. Transanal mucosectomy. Ileal pouch advancement for anorectal dysplasia or inflammation after restorative proctocolectomy. Dis Colon Rectum 1994; 37:1008-11.
54. Wu JS, McGannon EA, Church JM. Incidence of neoplastic polyps in the ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy. Dis Colon Rectum 1998; 41:552-6; discussion 56-7.
55. Parc YR, Olschwang S, Desaint B, et al. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 2001; 233:360-4.
56. Thompson-Fawcett MW, Marcus VA, Redston M, et al. Adenomatous polyps develop commonly in the ileal pouch of patients with familial adenomatous polyposis. Dis Colon Rectum 2001; 44:347-53.
57. van Duijvendijk P, Slors JF, Taat CW, et al. Functional outcome after colectomy and ileorectal anastomosis compared with proctocolectomy and ileal pouch-anal anastomosis in familial adenomatous polyposis. Ann Surg 1999; 230:648-54.
58. Madden MV, Neale KF, Nicholls RJ, et al. Comparison of morbidity and function after colectomy with ileorectal anastomosis or restorative proctocolectomy for familial adenomatous polyposis. Br J Surg 1991; 78:789-92.
59. Soravia C, Klein L, Berk T, et al. Comparison of ileal pouchanal anastomosis and ileorectal anastomosis in patients with familial adenomatous polyposis. Dis Colon Rectum 1999; 42:1028-33; discussion 33-4.
60. Kartheuser AH, Parc R, Penna CP, et al. Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Surgery 1996; 119:615-23.
61. Hassan I, Chua HK, Wolff BG, et al. Quality of life after ileal pouch-anal anastomosis and ileorectal anastomosis in patients with familial adenomatous polyposis. Dis Colon Rectum 2005; 48:2032-7.
62. Stoner GD, Budd GT, Ganapathi R, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 1999; 470:45-53.
63. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-6.
64. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-52.
65. Winde G, Schmid KW, Schlegel W, et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995; 38:813-30.
66. Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9:4756-60.
67. Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122:641-5.
68. Tonelli F, Valanzano R, Messerini L, et al. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?. J Surg Oncol 2000; 74:15-20.
69. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346:1054-9.
70. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 1995; 75:936-8.
71. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1993; 36:1059-62.
72. Bertario L, Presciuttini S, Sala P, et al. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 1994; 10:225-34.
73. Clark SK, Neale KF, Landgrebe JC, et al. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 1999; 86:1185-9.
74. Soravia C, Berk T, McLeod RS, et al. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:363-9.
75. Penna C, Tiret E, Parc R, et al. Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surg Gynecol Obstet 1993; 177:263-8.
76. Bertario L, Russo A, Sala P, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21:1698-707.
77. Church JM. Mucosal ischemia caused by desmoid tumors in patients with familial adenomatous polyposis: report of four cases. Dis Colon Rectum 1998; 41:661-3.
78. Heiskanen I, Jarvinen HJ. Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis 1996; 11:157-62.
79. Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:29-33.
80. Bus PJ, Verspaget HW, van Krieken JH, et al. Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol 1999; 11:1179-83.
81. Church J, Berk T, Boman BM, et al. Collaborative Group of the Americas on Inherited Colorectal Cancer. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum 2005; 48:1528-34.
82. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92:1259-64.
83. Skapek SX, Hawk BJ, Hoffer FA, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 1998; 16:3021-7.
84. Lynch HT, Fitzgibbons R Jr, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994; 37:260-7.
85. Poritz LS, Blackstein M, Berk T, et al. Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. Dis Colon Rectum 2001; 44:1268-73.
86. Chatzipetrou MA, Tzakis AG, Pinna AD, et al. Intestinal transplantation for the treatment of desmoid tumors associated with familial adenomatous polyposis. Surgery 2001; 129:277-81.
87. Church JM, McGannon E, Hull-Boiner S, et al. Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:1170-3.
88. Bulow S, Alm T, Fausa O, et al. Duodenal adenomatosis in familial adenomatous polyposis. DAF Project Group. Int J Colorectal Dis 1995; 10:43-6.
89. Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998; 85:742-50.
90. Alarcon FJ, Burke CA, Church JM, et al. Familial adenomatous polyposis: efficacy of endoscopic and surgical treatment for advanced duodenal adenomas. Dis Colon Rectum 1999; 42:1533-6.
91. Groves CJ, Saunders BP, Spigelman AD, et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002; 50:636-41.
92. Vasen HF, Bulow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997; 40:716-9.
93. Brosens LA, Keller JJ, Offerhaus GJ, et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 2005; 54:1034-43.
94. Wong RF, DiSario JA. Approaches to endoscopic ampullectomy. Curr Opin Gastroenterol 2004; 20:460-7.
95. Norton ID, Geller A, Petersen BT, et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001; 96:101-6.
96. Soravia C, Berk T, Haber G, et al. Management of advanced duodenal polyposis in familial adenomatous polyposis. J Gastrointest Surg 1997; 1:474-8.
97. Penna C, Bataille N, Balladur P, et al. Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis. Br J Surg 1998; 85:665-8.
98. Ruo L, Coit DG, Brennan MF, et al. Long-term follow-up of patients with familial adenomatous polyposis undergoing pancreaticoduodenal surgery. J Gastrointest Surg 2002; 6:671-5.
99. Kalady MF, Clary BM, Tyler DS, et al. Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg 2002; 6:82-7.
100. Phillips RK, Wallace MH, Lynch PM, et al. FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50:857-60.
101. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116:1453-6.
102. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34:424-5.
103. Lindor NM, Rabe K, Petersen GM, et al. Lower incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979-85.
104. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89:1758-62.
105. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261-8.
106. Fitzgibbons RJ Jr, Lynch HT, Stanislav GV, et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Ann Surg 1987; 206:289-95.
107. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002; 45:1588-94.
108. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-3.
109. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851-60.
110. Shia J, Klimstra DS, Nafa K, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005; 29:96-104.
111. De Jong AE, van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10:972-80.
112. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20:1043-8.
113. NCCN colorectal cancer screening practice guidelines National Comprehensive Cancer Network. Oncology (Huntingt) 1999; 13:152-79.
114. Lynch HT. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers?. Dis Colon Rectum 1996; 39:109-10.
115. Church JM. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996; 28:479-82.
116. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277:915-9.
117. Van Dalen R, Church J, McGannon E, et al. Patterns of surgery in patients belonging to Amsterdam-positive families. Dis Colon Rectum 2003; 46:617-20.
118. Rodriguez-Bigas MA, Vasen HF, Pekka-Mecklin J, et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg 1997; 225:202-7.
119. Lee JS, Petrelli NJ, Rodrigues-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg 2001; 181:207-10.
120. de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch gene defect. Gut 2003; 52:1752-5.
121. Lynch HT, Lynch JF, Fitzgibbons R Jr. Role of prophylactic colectomy in Lynch syndrome. Clin Colorectal Cancer 2003; 3:99-101.
122. Vasen HF, van Ballegooijen M, Buskens E, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82:1632-7.
123. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118:829-34.
124. Syngal S, Weeks JC, Schrag D, et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998; 129:787-96.
125. Scaife CL, Rodriguez-Bigas MA. Lynch syndrome: implications for the surgeon. Clin Colorectal Cancer 2003; 3:92-8.
126. Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995; 345:1183-4.
127. Moslein G, Nelson H, Thibodeau S, et al. Rectal carcinomas in HNPCC (in German). Langenbecks Arch Chir Suppl Kongressbd 1998; 115:1467-9.
128. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94:1708-12.
129. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82:223-8.
130. Shih HA, Couch FJ, Nathanson KL, et al. BRCA1 and BRCA2 mutation frequency in women evaluated in breast cancer risk evaluation clinic. J Clin Oncol 2002; 20:994-9.
131. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670-7.
132. Reedy M, Gallion H, Fowler JM, et al. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Cancer Res 2002; 85:255-9.
133. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807-16.
134. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60:496-504.
135. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews. N Engl J Med 1997; 336:1401-8.
136. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700-10.
137. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60:1013-20.
138. Thompson D, Easton DF. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358-65.
139. Deffenbaugh AM, Frank TS, Hoffman M, et al. Characterization of common BRCA1 and BRCA2 variants. Genet Test 2002; 6:119-21.
140. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995; 11:428-33.
141. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15:103-5.
142. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-5.
143. Lynch HT, Lemon SJ, Durham C, et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 1997; 79:2219-28.
144. Kauff ND, Scheuer L, Robson ME, et al. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 2001; 3:422-5.
145. Grann VR, Jacobson JS, Thomason D, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002; 20:2520-9.
146. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005; 23:6890-8.
147. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616-22.
148. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23:7804-10.
149. DiSaia PJ, Grosen EA, Kurosaki T, et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174:1494-8.
150. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795-7.
151. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71:2751-5.
152. Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995; 17:33-5.
153. Chen KT, Schooley JL, Flam MS. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 1985; 66:93S-94S.
154. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336:1125-30.
155. Berchuck A, Heron KA, Carney ME, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4:2433-7.
156. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001; 80:395-8.
157. Lavie O, Hornreich G, Ben Arie A, et al. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 2000; 96:28-32.
158. Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004; 92:521-4.
159. Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76:45-50.
160. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001; 80:341-5.
161. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 200; 94:1365-72.
162. Salazar H, Godwin AK, Daley MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88:1810-20.
163. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000; 89:383-90.
164. Stratton JF, Buckley CH, Lowe D, et al. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 1999; 91:626-8.
165. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18:2728-32.
166. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25:1283-9.
167. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23:127-32.
168. Colgan TJ, Boerner SL, Murphy J, et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Cancer Res 2002; 85:397-403.
169. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001; 80:176-80.
170. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339:424-8.
171. Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 2000; 18:19S-31S.
172. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105:569-74.
173. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999; 23:142-4.
174. Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993; 53:5853-5.
175. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-6.
176. Kowalski LD, Mutch DG, Herzog TJ, et al. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer 1997; 18:219-27.
177. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996; 56:4836-40.
178. Buttin BM, Powell MA, Mutch DG, et al. Increased risk for hereditary
179. Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003; 21:4364-70.
180. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96:516-20.
181. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6:105-10.
182. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42:491-6.
183. Vasen HF, Watson P, Mecklin JP, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994; 14:1675-8.
184. Brown GJ, St. John DJ, Macrae FA, et al. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 2001; 80:346-9.
185. Boks DE, Trujillo AP, Voogd AC, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002; 102:198-200.
186. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354:261-9.
187. Offit K, Kauff ND. Reducing the risk of gynecologic cancer in the Lynch syndrome. N Engl J Med 2006; 354:293-5.
188. Chung L, Boraddus R, Crozier M, et al. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 2003; 102:1152-5.
189. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2003; 288:321-33.
190. Baylin SB, Hsu SH, Gann DS, et al. Inherited medullary thyroid carcinoma: a final monoclonal mutation in one of multiple clones of susceptible cells. Science 1978; 199:429-31.
191. Wells SA, Baylin SB, Leight GS, et al. The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 1982; 195:595-9.
192. Gagel RF, Tashjian AH Jr, Cummings T, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988; 318:478-84.
193. Moley JF, Lairmore TC, Phay JE. Hereditary endocrinopathies. Curr Probl Surg 1999; 36:653-762.
194. Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2a: results of long-term follow-up. Surgery 1993; 114:1070-7.
195. Gagel RF, Levy ML, Donovan DT, et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989; 111:802-6.
196. Edery P, Lyonnet S, Mulligan LM, et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994; 367:378-80.
197. Romeo G, Ronchetto P, Luo Y, et al. Point mutations affecting the tyrosine kinase domain of the RET protooncogene in Hirschsprung's disease. Nature 1994; 367:377-8.
198. Cohen MS, Phay JE, Albinson C, et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 2002; 235:648-54.
199. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2:851-6.
200. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-60.
201. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994; 6:70-4.
202. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors, and Hirschsprung disease. Hum Mutat 1997; 9:97-109.
203. Libroa I. Familial medullary thyroid carcinoma: clinical management. Seventh International Workshop on Multiple Endocrine Neoplasia Italy: Gubbio; 1993.
204. Lips CJ, Landvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331:828-35.
205. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994; 220:237-50.
206. Decker RA, Geiger JD, Cox CE, et al. Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated?. World J Surg 1996; 20:814-20.
207. Frilling A, Dralle H, Eng C, et al. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995; 118:1099-104.
208. Pacini F, Romei C, Miccoli P, et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for RET gene mutations. Surgery 1995; 118:1031-5.
209. Learoyd DL, Marsh DJ, Richardson AL, et al. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch Surg 1997; 132:1022-5.
210. Frank-Raue K, Hoppner W, Buhr H, et al. Application of genetic screening in families with hereditary medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 1996; 104(Suppl 4):108-10.
211. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998; 22:744-50.
212. Skinner MA, DeBenedetti MK, Moley JF, et al. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996; 31:177-82.
213. Skinner MA, Moley J, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005; 353:1105-13.
214. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995; 238:343-6.
215. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999; 229:880-8.